Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Ongoing Losses • Equity Dilution ELVN is well-capitalized with strong liquidity and minimal debt, but absent revenue, persistent cash losses, shareholder dilution, and elevated price-to-book valuation make the stock high-risk.
Price Behavior
Key Price Behavior Insights: • Lower highs • Support test • Oversold momentum Support Level: $54.30 Resistance Level: $57.80–$59.40 ELVN is bearish over the last month, down 6.4% to $54.32 below its average, with $54.30 support critical despite oversold rebound potential.
Sentiment & News
Key News Insights: • Analyst Upgrade • BlackRock Stake • Trial Momentum Enliven's bullish analyst coverage, BlackRock stake, promising ELVN-001 Phase 1 data, and strong cash runway strengthen its CML investment case.
AI Summary
ELVN's ~$895M cash runway shifts the investment case from financing survival to a high-valuation clinical proof point: investors should accumulate only if ENABLE-2 can validate ELVN-001's differentiated, durable CML efficacy and tolerability, as a pivotal-data setback would disproportionately impair this single-asset story.
Description
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer treatment. Its lead programs include ELVN-001, in a Phase 1 study for chronic myeloid leukemia, and ELVN-002, recently activated in a Phase 1 trial for tumors with HER2 alterations; the company is headquartered in Boulder, Colorado.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | ELVN | Enliven Therapeutics, Inc. | ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade. | Closed | -1.2% |